NASDAQ:TTNPTitan Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.30 0.00 (-0.20 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$0.29Now: $0.30▼$0.3050-Day Range$0.28MA: $0.31▼$0.4152-Week Range$0.14Now: $0.30▼$0.79Volume3.12 million shsAverage Volume5.54 million shsMarket Capitalization$28.70 millionP/E RatioN/ADividend YieldN/ABeta0.89 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTitan Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Titan Pharmaceuticals has a potential upside of 233.3% from its current price of $0.30.Amount of Analyst CoverageTitan Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesTitan Pharmaceuticals has received 328 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTitan Pharmaceuticals has received 297 “underperform” votes. (Add your “underperform” vote.)Community SentimentTitan Pharmaceuticals has received 52.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote “Outperform” if you believe TTNP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TTNP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTitan Pharmaceuticals does not currently pay a dividend.Dividend GrowthTitan Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Titan Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.94% of the stock of Titan Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 2.97% of the stock of Titan Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Titan Pharmaceuticals are expected to decrease in the coming year, from ($0.13) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Titan Pharmaceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Titan Pharmaceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTitan Pharmaceuticals has a P/B Ratio of 15.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTNP Previous Symbol CUSIPN/A CIK910267 Webwww.titanpharm.com Phone650-244-4990Debt Debt-to-Equity Ratio0.68 Current Ratio2.75 Quick Ratio2.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.61 million Price / Sales7.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book15.00Profitability EPS (Most Recent Fiscal Year)($0.72) Net Income$-16,460,000.00 Net Margins-437.91% Return on Equity-1,909.37% Return on Assets-190.56%Miscellaneous Employees23 Outstanding Shares95,660,000Market Cap$28.70 million Next Earnings Date8/12/2020 (Estimated) OptionableOptionable $0.30 0.00 (-0.20 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TTNP News and Ratings via Email Sign-up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions How has Titan Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Titan Pharmaceuticals' stock was trading at $0.2445 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TTNP shares have increased by 22.7% and is now trading at $0.30. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Titan Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Titan Pharmaceuticals. When is Titan Pharmaceuticals' next earnings date? Titan Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Titan Pharmaceuticals. How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its quarterly earnings data on Friday, May, 15th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter. The specialty pharmaceutical company had revenue of $1.34 million for the quarter. Titan Pharmaceuticals had a negative net margin of 437.91% and a negative return on equity of 1,909.37%. View Titan Pharmaceuticals' earnings history. When did Titan Pharmaceuticals' stock split? How did Titan Pharmaceuticals' stock split work? Titan Pharmaceuticals's stock reverse split on the morning of Friday, January 25th 2019. The 1-6 reverse split was announced on Thursday, January 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 24th 2019. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 17 shares after the split. What price target have analysts set for TTNP? 1 Wall Street analysts have issued 12-month price targets for Titan Pharmaceuticals' shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Titan Pharmaceuticals' stock price to reach $1.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View analysts' price targets for Titan Pharmaceuticals. Has Titan Pharmaceuticals been receiving favorable news coverage? Headlines about TTNP stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Titan Pharmaceuticals earned a daily sentiment score of -2.5 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Titan Pharmaceuticals. Who are some of Titan Pharmaceuticals' key competitors? Some companies that are related to Titan Pharmaceuticals include Creative Realities (CRDF), Champions Oncology (CSBR), La Jolla Pharmaceutical (LJPC), Gamida Cell (GMDA), AIM ImmunoTech (AIM), Organovo (ONVO), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), TrovaGene (TROV), Polarityte (PTE), Genetic Technologies (GENE), Curis (CRIS), Microbot Medical (MBOT), aTyr Pharma (LIFE) and Acorda Therapeutics (ACOR). View all competitors. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), OrganiGram (OGI), Zosano Pharma (ZSAN), Miragen Therapeutics (MGEN), (CHK), Seanergy Maritime (SHIP) and Unum Therapeutics (UMRX). Who are Titan Pharmaceuticals' key executives? Titan Pharmaceuticals' management team includes the following people: Dr. Marc Rubin, Exec. Chairman (Age 64)Mr. Sunil Bhonsle, Pres, CEO, Principal Financial Officer & Director (Age 69)Dr. Katherine L. Beebe-DeVarney Ph.D., Exec. VP & Chief Scientific Officer (Age 58)Mr. Dane D. Hallberg, Exec. VP & Chief Commercial Officer (Age 50) What is Titan Pharmaceuticals' stock symbol? Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP." Who are Titan Pharmaceuticals' major shareholders? Titan Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.15%) and UBS Group AG (0.12%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Marc Rubin and Sunil Bhonsle. View institutional ownership trends for Titan Pharmaceuticals. Which institutional investors are buying Titan Pharmaceuticals stock? TTNP stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and UBS Group AG. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Marc Rubin, and Sunil Bhonsle. View insider buying and selling activity for Titan Pharmaceuticals. How do I buy shares of Titan Pharmaceuticals? Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Titan Pharmaceuticals' stock price today? One share of TTNP stock can currently be purchased for approximately $0.30. How big of a company is Titan Pharmaceuticals? Titan Pharmaceuticals has a market capitalization of $28.70 million and generates $3.61 million in revenue each year. The specialty pharmaceutical company earns $-16,460,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Titan Pharmaceuticals employs 23 workers across the globe. What is Titan Pharmaceuticals' official website? The official website for Titan Pharmaceuticals is www.titanpharm.com. How can I contact Titan Pharmaceuticals? Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
